RPS26A Antibody

What is RPS26 and what cellular functions does it perform?

RPS26 is a critical component of the 40S ribosomal subunit, playing an essential role in ribosome biogenesis and protein synthesis. The protein contains a eukaryote-specific 62-YXXPKXYXK-70 (Y62–K70) motif that interacts with the 5′ untranslated region of mRNA, suggesting its specific role during translation initiation. Studies have demonstrated that RPS26 is necessary for normal 40S subunit formation and efficient 80S ribosome assembly. Dysregulation of RPS26 has been implicated in various diseases, including Diamond-Blackfan anemia and cancer, making it a significant target for research and potential therapeutic interventions .

The protein has a calculated molecular weight of 13 kDa, though it typically appears at 18-21 kDa in experimental contexts due to post-translational modifications. RPS26 is highly conserved across species, with human RPS26 sharing approximately 63% amino acid sequence identity with yeast RPS26 .

What are the validated applications for RPS26A antibodies?

RPS26A antibodies have been validated for multiple experimental applications, allowing researchers to investigate this protein across various contexts:

It is strongly recommended to optimize these dilutions for each specific experimental system to obtain optimal results, as antibody performance can be sample-dependent .

How should RPS26A antibodies be stored and handled to maintain reactivity?

Proper storage and handling of RPS26A antibodies are crucial for maintaining their reactivity and specificity. Most commercially available RPS26A antibodies should be stored at -20°C, where they typically remain stable for at least one year after shipment. Many are supplied in PBS buffer containing 0.02% sodium azide and 50% glycerol (pH 7.3), which helps maintain stability. Contrary to some antibodies, aliquoting is generally unnecessary for -20°C storage of these preparations .

When working with RPS26A antibodies, avoid repeated freeze-thaw cycles, which can degrade the antibody and reduce its effectiveness. Always centrifuge the antibody vial briefly before opening to bring down any solution that might be in the cap. For smaller quantities (20μl sizes), some preparations may contain 0.1% BSA as a stabilizing agent .

What reactivity profiles do different RPS26A antibodies exhibit?

RPS26A antibodies demonstrate varied reactivity profiles depending on their origin and production methods:

When selecting an RPS26A antibody, researchers should choose one with demonstrated reactivity to their species of interest. If working with uncommon model organisms, preliminary validation tests are strongly recommended before proceeding with full experiments .

How do mutations in the Y62-K70 motif of RPS26 affect ribosome assembly and function?

Research on the eukaryote-specific 62-YXXPKXYXK-70 (Y62–K70) motif within RPS26 has revealed fascinating insights into ribosome assembly dynamics. Studies using alanine-scanning mutagenesis in Saccharomyces cerevisiae have demonstrated that single amino acid substitutions within this motif do not significantly affect in vivo function. Surprisingly, even a mutant with simultaneous replacement of 5 conserved amino acid residues (Y62, P65, K66, Y68, and K70) by alanine (Rps26a 5A) remained functional under standard conditions, showing growth defects only at low temperatures or alkaline pH .

The data indicates that mutations affecting this region cause combined defects in subunit joining and 40S subunit deficiency. Specifically, quantification of the 40S and 60S peaks in polysome profiles clearly demonstrated a shortage of 40S subunits in strains expressing Rps26a 5A or human RPS26. These findings highlight the critical role of the Y62-K70 motif in maintaining proper ribosome stoichiometry and function .

What are the implications of RPS26 dysregulation in Diamond-Blackfan anemia?

Diamond-Blackfan anemia (DBA) is a congenital red cell aplasia typically diagnosed during early infancy that has been linked to mutations in ribosomal protein genes, including RPS26. The connection between RPS26 mutations and DBA illustrates how ribosomal protein defects can lead to specific disease phenotypes despite their ubiquitous cellular functions .

Research suggests that mutations affecting RPS26 lead to impaired 40S ribosomal subunit formation, which is particularly detrimental to erythroid progenitor cells that require robust protein synthesis during differentiation. The resulting imbalance in ribosomal subunits activates cellular stress responses, including p53-mediated apoptosis in erythroid precursors, manifesting as the red cell aplasia characteristic of DBA .

Studies examining ribosome profiles in cells with RPS26 mutations show increased 60S peaks and reduced 40S:60S ratios, similar to the patterns observed in experimental yeast models with Y62-K70 motif mutations. This concordance supports the mechanistic link between defective RPS26 function, ribosome assembly disruption, and the development of DBA .

The specific targeting of erythroid lineage by RPS26 mutations likely involves specialized translational programs in these cells. Understanding these mechanisms could provide insights for developing targeted therapies for DBA patients with RPS26 mutations.

How can researchers troubleshoot non-specific binding when using RPS26A antibodies?

Non-specific binding is a common challenge when working with antibodies, including those targeting RPS26A. Effective troubleshooting requires systematic optimization of multiple parameters:

• Optimize antibody dilution: Test a range of dilutions around the recommended values (1:500-1:2000 for Western blot). Excessive antibody concentration often increases background signal .

• Blocking optimization: Use 5% non-fat dry milk or 3-5% BSA in TBST. For challenging samples, test alternative blocking agents like normal serum from the secondary antibody host species or commercial blocking reagents.

• Increase washing frequency and duration: Add an additional wash step after secondary antibody incubation (4-5 washes of 5-10 minutes each with TBST).

• Sample preparation modifications: Add protease and phosphatase inhibitors to protein extraction buffers. Heat samples at 70°C rather than 95-100°C to minimize protein aggregation for membrane proteins.

• Include appropriate controls: Always include a positive control sample (mouse ovary tissue, mouse lung tissue, or human cell lines like U-251MG) where RPS26A is known to be expressed. Consider using knockout/knockdown samples as negative controls when available .

• Cross-reactivity testing: If non-specific binding persists, pre-adsorb the antibody with the immunizing peptide or perform peptide competition assays to determine if observed bands are specific to RPS26A.

For immunohistochemistry applications specifically, consider optimizing antigen retrieval methods. Data indicates that TE buffer pH 9.0 works well for RPS26A detection, though citrate buffer pH 6.0 is an acceptable alternative .

What controls should be included when using RPS26A antibodies in knockout/knockdown studies?

Designing rigorous controls for RPS26A knockout/knockdown studies is essential for reliable data interpretation:

• Positive expression controls: Include wildtype samples with known RPS26A expression. Based on published data, mouse ovary and lung tissues or cell lines such as MCF-7, U-251MG, and DU145 reliably express detectable levels of RPS26A .

• Knockout validation: When using CRISPR-Cas9 or other gene editing approaches for RPS26A knockout, sequence the targeted region to confirm the mutation. Studies in yeast have shown that complete deletion of both RPS26A and RPS26B is lethal, suggesting that complete knockout in mammalian cells may also be lethal, necessitating conditional systems .

• Knockdown efficiency controls: For siRNA or shRNA approaches, quantify knockdown efficiency using both RT-qPCR (for mRNA levels) and Western blot (for protein levels). Aim for at least 70-80% reduction for meaningful functional studies.

• Rescue controls: Express exogenous RPS26A (potentially RPS26A from another species or with silent mutations to evade knockdown) to demonstrate that observed phenotypes are specifically due to RPS26A loss rather than off-target effects.

• Functional readouts: Monitor ribosome profiles using sucrose gradient centrifugation to assess the impact on 40S:60S ratios, similar to methods used in yeast studies. The expected phenotype would include an increase in free 60S subunits similar to that observed with the Rps26a 5A mutation in yeast .

• Impact on related ribosomal proteins: Assess whether RPS26A knockdown affects the levels of interacting ribosomal proteins to understand compensatory mechanisms.

When analyzing results, remember that the observed molecular weight of RPS26 typically ranges from 18-21 kDa despite a calculated weight of 13 kDa, likely due to post-translational modifications .

How can antigen retrieval protocols be optimized for RPS26A immunohistochemistry?

Effective antigen retrieval is critical for successful RPS26A detection in formalin-fixed, paraffin-embedded (FFPE) tissues. Based on experimental validation data, the following optimization strategy is recommended:

• Buffer selection: TE buffer at pH 9.0 is the primary recommended buffer for RPS26A antigen retrieval. As an alternative, citrate buffer at pH 6.0 can also yield acceptable results, though potentially with lower signal intensity .

• Heat-induced epitope retrieval (HIER): Use either:

  • Pressure cooker method: 3 minutes at full pressure in the appropriate buffer

  • Microwave method: 10-20 minutes at medium power in the appropriate buffer

  • Water bath: 95°C for 20-30 minutes

• Tissue-specific optimization: Different tissues may require modified protocols:

  • For human breast cancer tissue: Extended retrieval time (25-30 minutes) in TE buffer pH 9.0 has shown optimal results

  • For human kidney tissue: Standard protocol in TE buffer pH 9.0 is typically sufficient

• Antibody concentration adjustment: After optimizing antigen retrieval, re-optimize antibody dilution. Begin testing in the range of 1:20-1:200, as recommended .

• Signal amplification: For weak signals after optimization, consider using polymer-based detection systems or tyramide signal amplification methods to enhance sensitivity while maintaining specificity.

• Background reduction: If background staining occurs, add a peroxidase blocking step (3% H₂O₂ for 10 minutes) before antibody incubation and increase washing steps between incubations.

Validation studies have demonstrated that optimized antigen retrieval protocols significantly improve the signal-to-noise ratio for RPS26A detection in human breast cancer and kidney tissues .

How is RPS26A expression altered in cancer, and what are the best approaches for quantification?

RPS26A expression alterations have been observed in various cancers, making accurate quantification essential for understanding its potential role in oncogenesis. Current research indicates that optimal quantification approaches depend on the specific research question:

• Western blot quantification: For relative protein expression levels, Western blot with normalization to housekeeping proteins (β-actin, GAPDH) is effective. The recommended antibody dilution range is 1:500-1:2000 . Signal should be quantified using densitometry software with background subtraction.

• Immunohistochemical scoring: For tissue samples, semi-quantitative scoring systems such as H-score or Allred score can be applied. This combines staining intensity (0-3+) with percentage of positive cells to generate a composite score. RPS26A typically shows cytoplasmic and nuclear staining patterns in positive samples .

• RNA-level quantification: RT-qPCR with appropriate reference genes (often GAPDH, ACTB, or 18S rRNA) provides mRNA expression data. This should be complemented with protein-level analysis given potential post-transcriptional regulation.

• Single-cell approaches: For heterogeneous tumors, single-cell RNA sequencing or multiplexed immunofluorescence may better capture the variability of RPS26A expression across different tumor cell populations.

When interpreting RPS26A expression data in cancer contexts, researchers should consider that:

• Both overexpression and underexpression have been reported in different cancer types

• RPS26A function may be context-dependent, necessitating correlation with clinical parameters

• Analysis should account for potential relationships with ribosome biogenesis more broadly

For cancer cell line studies, U-251MG, LO2, Raji, and DU145 have been validated as positive controls for RPS26A expression .

What is the significance of RPS26A in yeast models, and how do findings translate to mammalian systems?

Yeast models have provided valuable insights into RPS26A function, with both similarities and differences compared to mammalian systems:

These yeast findings have translational relevance for understanding human diseases like Diamond-Blackfan anemia, where RPS26 mutations affect ribosome biogenesis leading to specific cellular pathologies. Researchers using yeast models should be aware of both the conservation and divergence between these systems when extrapolating to mammalian biology.

How does RPS26A interact with other ribosomal and non-ribosomal proteins?

RPS26A participates in complex protein-protein interaction networks that influence ribosome assembly, function, and potential extraribosomal activities:

• Ribosomal protein interactions: RPS26A is positioned at the interface between the small ribosomal subunit (40S) and mRNA, where it interacts with other ribosomal proteins including RPS1, RPS14, and RPS26. These interactions are critical for the structural integrity of the 40S subunit and for mRNA binding during translation initiation .

• mRNA interaction specificity: The eukaryote-specific Y62-K70 motif of RPS26 directly interacts with the 5′ untranslated region of mRNA, potentially contributing to transcript-specific translation regulation. This suggests that RPS26A may participate in selecting which mRNAs are preferentially translated under different conditions .

• Assembly factors: During ribosome biogenesis, RPS26A interacts with assembly factors and chaperones that facilitate its incorporation into the pre-40S ribosomal subunit. Disruption of these interactions, as seen in some mutants, can lead to defects in 40S subunit formation and accumulation of free 60S subunits .

• Impact on subunit joining: Studies of ribosome profiles in yeast expressing mutant forms of RPS26A (such as Rps26a 5A) or human RPS26 reveal increased amounts of free 60S subunits. This suggests that RPS26A influences the efficiency of subunit joining during translation initiation, potentially through interactions with initiation factors .

Understanding these interaction networks is crucial for interpreting experimental data from RPS26A studies. When using RPS26A antibodies for immunoprecipitation, researchers can expect to pull down not only RPS26A itself but also its interacting partners, providing insight into its functional complexes in different cellular contexts.

What are the key considerations when selecting between polyclonal and monoclonal RPS26A antibodies?

The choice between polyclonal and monoclonal RPS26A antibodies should be guided by specific experimental requirements:

Polyclonal antibodies (e.g., 14909-1-AP, CAB15096):

• Advantages: Recognize multiple epitopes on RPS26A, potentially increasing detection sensitivity; may be more robust to minor protein denaturation or modifications; often more cost-effective.

• Best applications: Western blotting, immunoprecipitation, and immunohistochemistry where signal strength is prioritized.

• Limitations: Batch-to-batch variability; may have higher background in some applications; potential for cross-reactivity .

Monoclonal antibodies:

• Advantages: Consistent specificity between batches; reduced background in some applications; highly selective for specific epitopes.

• Best applications: Flow cytometry, specialized immunohistochemistry; experiments requiring absolute epitope specificity.

• Limitations: May be more sensitive to epitope masking or denaturation; typically more expensive; potentially lower signal strength.

When selecting an RPS26A antibody, researchers should consider:

• The specific application (WB, IHC, IF, IP)

• The species being studied (human, mouse, rat)

• The need for batch consistency in long-term studies

• The specific epitope region of interest

For most general research applications, published data indicates that polyclonal antibodies like 14909-1-AP have been successfully employed across multiple applications and species .

How should researchers interpret differences between calculated and observed molecular weights for RPS26?

The discrepancy between the calculated molecular weight of RPS26 (13 kDa) and its observed molecular weight in experimental systems (18-21 kDa) is a common source of confusion . This phenomenon has several potential explanations that researchers should consider when interpreting Western blot results:

• Post-translational modifications: RPS26 undergoes various modifications including phosphorylation and ubiquitination that increase its apparent molecular weight. These modifications may vary between cell types and physiological conditions.

• Protein-protein interactions: Some protein complexes may be resistant to complete denaturation, leading to higher molecular weight bands.

• Alternative splicing: Though not extensively documented for RPS26, alternative splicing could potentially contribute to size variations.

• Technical factors affecting migration: SDS-PAGE conditions, including gel percentage, buffer composition, and running conditions can influence protein migration patterns.

For accurate data interpretation, researchers should:

• Always include positive control samples with known RPS26 expression (e.g., mouse ovary tissue, mouse lung tissue) to establish the expected migration pattern .

• Consider treating samples with phosphatase or deubiquitinase to assess the contribution of these modifications to the observed weight.

• When reporting results, specify both the calculated (13 kDa) and observed (18-21 kDa) molecular weights to avoid confusion.

• In cases of unexpected band patterns, confirm specificity through additional methods such as immunoprecipitation followed by mass spectrometry.

The consistent observation of RPS26 at 18-21 kDa across multiple studies suggests this is its typical migration pattern in standard experimental systems despite theoretical calculations .

How is RPS26A research contributing to our understanding of specialized ribosomes?

Recent advances in ribosome biology suggest the existence of "specialized ribosomes" with unique compositions that preferentially translate specific mRNA subsets. RPS26A research is providing valuable insights into this emerging field:

• Transcript selectivity: The positioning of RPS26 at the interface between the 40S subunit and mRNA, particularly through its Y62-K70 motif, suggests it may influence which transcripts are preferentially translated. This could contribute to specialized translation programs in different cell types or under different conditions .

• Tissue-specific effects of mutations: The observation that RPS26 mutations predominantly affect erythroid lineages in Diamond-Blackfan anemia, despite RPS26 being ubiquitously expressed, supports the concept that different tissues may have distinct requirements for specific ribosomal protein variants or modifications.

• Regulatory flexibility: Studies in yeast show that single amino acid substitutions within the conserved Y62-K70 motif do not substantially impact growth under standard conditions but reveal phenotypes under stress conditions. This suggests RPS26 may contribute to translational adaptation under changing environments .

• Interaction with regulatory factors: RPS26's position on the ribosome may facilitate interactions with specialized translation initiation factors or regulatory RNAs that modulate transcript-specific translation.

Future research directions in this area could include:

• Ribosome profiling studies comparing wildtype and RPS26 mutant cells to identify differentially translated mRNAs

• Structural studies of how RPS26 variants affect ribosome conformation and mRNA interaction

• Investigation of tissue-specific RPS26 modifications and their functional consequences

The evolving understanding of RPS26A in specialized ribosome function may open new therapeutic avenues for diseases involving ribosomal dysfunction.

What are promising applications of RPS26A antibodies in cancer research?

RPS26A antibodies are emerging as valuable tools in cancer research, with several promising applications:

• Diagnostic and prognostic biomarker development: RPS26A expression alterations have been observed in various cancers. Antibody-based detection methods can help establish whether RPS26A levels correlate with clinical outcomes or treatment responses across cancer types .

• Understanding ribosome heterogeneity in tumors: Cancer cells often exhibit dysregulated translation. RPS26A antibodies can help characterize ribosome composition changes in tumors, potentially revealing novel therapeutic vulnerabilities specific to cancer ribosomes.

• Monitoring therapy response: Changes in RPS26A expression or localization following treatment may serve as indicators of cellular stress responses or adaptation. Antibody-based methods can track these changes in patient samples or experimental models.

• Identifying cancer-specific RPS26A interacting partners: Immunoprecipitation with RPS26A antibodies followed by mass spectrometry can reveal cancer-specific protein interactions that might represent novel therapeutic targets.

• Investigating non-canonical functions: Beyond its role in ribosomes, RPS26A may have extraribosomal functions relevant to cancer biology. Antibodies enable investigation of these potential roles through techniques like proximity ligation assays to detect novel interactions.

In immunohistochemistry applications specifically, RPS26A antibodies have been validated for human breast cancer tissue analysis, with recommended dilutions of 1:20-1:200 using TE buffer pH 9.0 for antigen retrieval . This provides a methodological foundation for larger-scale cancer tissue studies.